|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis Vlстатья
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 6 октября 2021 г.
- Авторы: Kreuter J., Mühlstein A., Gelperina S.
- Журнал: Die Pharmazie
- Том: 68
- Номер: 7
- Год издания: 2013
- Издательство: Govi Verlag Pharmazeutischer Verlag GmbH
- Местоположение издательства: Germany
- Первая страница: 549
- Последняя страница: 554
- DOI: 10.1691/ph.2013.6502
- Аннотация: Lysosomal storage disorders like mucopolysaccharidosis (MPS) VI are rare diseases with a lack of wellsuited treatments. Even though an enzyme replacement therapy ERT) of recombinant arylsulfatase B (ASB) is available for MPS VI, the administration cannot positively affect the neurologic manifestations such as spinal cord ompression. Since nanoparticles (NP) have shown to be effective drug carriers, the feasibility of arylsulfatase B adsorption onto poly(butyl cyanoacrylate) (PBCA) nanoparticles was investigated in this study. In order to advance the ERT of ASB, the adsorption of the latter on the surface of PBCA NP as well as in vitro release in serum was investigated. With alteration of parameters like temperature, incubation time, pH, and enzyme amount, the adsorption process revealed to be stable with a maximum capacity of 67 g/mg NP at a pH of 6.3. In vitro release experiments demonstrated that the adsorption is stable for at least 60 minutes in human blood serum, indicating that the ASB-loaded PBCA nanoparticles represent a promising candidate for ERT of MPS VI.
- Добавил в систему: Гельперина Светлана Эммануиловна